

TRADEMARK ASSIGNMENT COVER SHEET

Electronic Version v1.1
Stylesheet Version v1.2

ETAS ID: TM509359

SUBMISSION TYPE:	NEW ASSIGNMENT		
NATURE OF CONVEYANCE:	ASSIGNMENT OF THE ENTIRE INTEREST AND THE GOODWILL		
CONVEYING PARTY DATA			
Name	Formerly	Execution Date	Entity Type
CEM-102 Pharmaceuticals, Inc.		02/08/2019	Corporation:
RECEIVING PARTY DATA			
Name:	Arrebus, Inc.		
Street Address:	2443 Lynn Road, Suite 210		
City:	Raleigh		
State/Country:	NORTH CAROLINA		
Postal Code:	27612		
Entity Type:	Corporation: DELAWARE		
PROPERTY NUMBERS Total: 1			
Property Type	Number	Word Mark	
Serial Number:	87392421	STAFREL	
CORRESPONDENCE DATA			
Fax Number:			
<i>Correspondence will be sent to the e-mail address first; if that is unsuccessful, it will be sent using a fax number, if provided; if that is unsuccessful, it will be sent via US Mail.</i>			
Phone:	9195785693		
Email:	lyle.gravatt@forrestfirm.com		
Correspondent Name:	William Lyle Gravatt		
Address Line 1:	406 Blackwell Street, Suite 420		
Address Line 4:	Durham, NORTH CAROLINA 27701		
NAME OF SUBMITTER:	William Lyle Gravatt		
SIGNATURE:	/William Lyle Gravatt/		
DATE SIGNED:	02/08/2019		
Total Attachments: 2			
source=TM Assignment - Stafrel signed#page1.tif			
source=TM Assignment - Stafrel signed#page2.tif			

CH \$40.00 87392421

TRADEMARK ASSIGNMENT

WHEREAS, the undersigned, **CEM-102 Pharmaceuticals, Inc.** (hereinafter "Assignor"), is the owner of the U.S. trademark application for STAFREL ("trademark") which is presently pending in the United States Patent and Trademark Office as follows:

Serial Application Number: 87/392,421

Date of Application: March 30, 2017

AND, WHEREAS, **Arrevas, Inc.**, having a place of business at 2443 Lynn Road, Suite 210, Raleigh, North Carolina 27612 (hereinafter "Assignee"), has acquired all right, title, and interest in the trademark, including the goodwill symbolized and associated with the trademark, by and through an Asset Purchase Agreement dated December 19, 2018 between Assignor and Assignee. In avoidance of doubt, Assignor does hereby sell, assign, transfer, and set over to Assignee, its successors, and assigns, all right, title, and interest in said trademark, together with the goodwill symbolized by the mark, and any other rights; provided that the transfer of such application accompanies, pursuant to the Asset Purchase Agreement, the transfer of Assignor's portion of the business to which the trademark pertains, and that business is ongoing and existing.

Assignor warrants that it is the legal owner of all right, title, and interest in the trademark, that the trademark has not been otherwise previously pledged, assigned, or encumbered and that this assignment does not infringe on the rights of any person. Assignor agrees to cooperate with Assignee to carry out any additional documents or other tasks necessary to carry out this assignment.

Assignee is to execute and deliver all papers, instruments, and assignments as may be necessary to vest all right, title, and interest in and to the aforesaid trademark, including, without limitation, recordation of the assignment in the United States Patent and Trademark Office.

[SIGNATURE PAGE FOLLOWS]

Trademark Assignment

Executed this 8th day of February, 2019.




Arrevas, Inc.

Name: Cam Kraus

Title: CEO

Executed this 8th day of February, 2019.



CENT-02 Pharmaceuticals, Inc.

Name: Peter J. Milligan

Title: CFO